- call +1-201-465-4211
- email sales@mrinsights.biz
Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells.
Scope of the Report:
This report studies the Breast Cancer Monoclonal Antibodies market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Breast Cancer Monoclonal Antibodies market by product type and applications/end industries.
The breast cancer monoclonal antibodies (mAbs) market is one of the fastest-growing segments of the global mAbs market and has gained major research significance among biotech and pharmaceutical companies due to the presence of high unmet needs in this area. Antibodies are increasingly becoming the best choice to treat cancers, including breast cancer. The use of antibody-drug conjugates (ADCs),including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is increasing rapidly. ADCs are highly effective cytotoxic drugs linked to mAbs. These drugs have shown to be potent and efficient in treating breast cancer. This has propelled vendors to focus on novel technologies such as Seattle Genetics (SGEN), ImmunoGen (IMGN), and Immunomedics (IMMU). The rising use of these antibodies in drug development increases revenue generation in the breast cancer mAbs market, contributing to market growth.
The breast cancer mAbs market in APAC will witness a high growth rate during the forecast period due to the better market penetration of breast cancer mAbs and biosimilars in emerging economies, especially in Japan, Australia, India, South Korea, and China. The rising number of initiatives undertaken by major vendors to assist patients in these countries is a significant contributor to the rise in sales of breast cancer mAbs in these countries. Moreover, the growing awareness about breast cancer and the available treatment alternatives will also propel growth prospects for the market growth in APAC.
The global Breast Cancer Monoclonal Antibodies market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Breast Cancer Monoclonal Antibodies.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Amgen
Roche
Mylan
Array BioPharma
Biocad
Boehringer Ingelheim
Bristol-Myers Squibb
Celldex Therapeutics
Celltrion
Daiichi Sankyo
GlaxoSmithKline
Immunomedics
MacroGenics
Merck
Novartis
Oncothyreon
Pfizer
Puma Biotechnology
Seattle Genetics
Sun Pharmaceutical Industries
Synta Pharmaceuticals
Teva Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Naked MAbs
Conjugated MAbs
Market Segment by Applications, can be divided into
Hospitals
Retail Pharmacies
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Breast Cancer Monoclonal Antibodies Market Overview
1.1 Product Overview and Scope of Breast Cancer Monoclonal Antibodies
1.2 Classification of Breast Cancer Monoclonal Antibodies by Types
1.2.1 Global Breast Cancer Monoclonal Antibodies Revenue Comparison by Types (2017-2023)
1.2.2 Global Breast Cancer Monoclonal Antibodies Revenue Market Share by Types in 2017
1.2.3 Naked MAbs
1.2.4 Conjugated MAbs
1.3 Global Breast Cancer Monoclonal Antibodies Market by Application
1.3.1 Global Breast Cancer Monoclonal Antibodies Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Retail Pharmacies
1.3.4 Others
1.4 Global Breast Cancer Monoclonal Antibodies Market by Regions
1.4.1 Global Breast Cancer Monoclonal Antibodies Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Breast Cancer Monoclonal Antibodies Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Breast Cancer Monoclonal Antibodies Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Breast Cancer Monoclonal Antibodies Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Breast Cancer Monoclonal Antibodies Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Breast Cancer Monoclonal Antibodies Status and Prospect (2013-2023)
1.5 Global Market Size of Breast Cancer Monoclonal Antibodies (2013-2023)
2 Manufacturers Profiles
2.1 Amgen
2.1.1 Business Overview
2.1.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Amgen Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.2 Roche
2.2.1 Business Overview
2.2.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Roche Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.3 Mylan
2.3.1 Business Overview
2.3.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Mylan Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.4 Array BioPharma
2.4.1 Business Overview
2.4.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Array BioPharma Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.5 Biocad
2.5.1 Business Overview
2.5.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Biocad Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.6 Boehringer Ingelheim
2.6.1 Business Overview
2.6.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Boehringer Ingelheim Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.7 Bristol-Myers Squibb
2.7.1 Business Overview
2.7.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Bristol-Myers Squibb Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.8 Celldex Therapeutics
2.8.1 Business Overview
2.8.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Celldex Therapeutics Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.9 Celltrion
2.9.1 Business Overview
2.9.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Celltrion Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.10 Daiichi Sankyo
2.10.1 Business Overview
2.10.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Daiichi Sankyo Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.11 GlaxoSmithKline
2.11.1 Business Overview
2.11.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 GlaxoSmithKline Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.12 Immunomedics
2.12.1 Business Overview
2.12.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Immunomedics Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.13 MacroGenics
2.13.1 Business Overview
2.13.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 MacroGenics Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.14 Merck
2.14.1 Business Overview
2.14.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Merck Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.15 Novartis
2.15.1 Business Overview
2.15.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Novartis Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.16 Oncothyreon
2.16.1 Business Overview
2.16.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Oncothyreon Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.17 Pfizer
2.17.1 Business Overview
2.17.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Pfizer Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.18 Puma Biotechnology
2.18.1 Business Overview
2.18.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Puma Biotechnology Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.19 Seattle Genetics
2.19.1 Business Overview
2.19.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Seattle Genetics Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.20 Sun Pharmaceutical Industries
2.20.1 Business Overview
2.20.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 Sun Pharmaceutical Industries Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.21 Synta Pharmaceuticals
2.21.1 Business Overview
2.2.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 Synta Pharmaceuticals Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
2.22 Teva Pharmaceuticals
2.22.1 Business Overview
2.22.2 Breast Cancer Monoclonal Antibodies Type and Applications
2.22.2.1 Product A
2.22.2.2 Product B
2.22.3 Teva Pharmaceuticals Breast Cancer Monoclonal Antibodies Revenue, Gross Margin and Market Share (2016-2017)
3 Global Breast Cancer Monoclonal Antibodies Market Competition, by Players
3.1 Global Breast Cancer Monoclonal Antibodies Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Breast Cancer Monoclonal Antibodies Players Market Share
3.2.2 Top 10 Breast Cancer Monoclonal Antibodies Players Market Share
3.3 Market Competition Trend
4 Global Breast Cancer Monoclonal Antibodies Market Size by Regions
4.1 Global Breast Cancer Monoclonal Antibodies Revenue and Market Share by Regions
4.2 North America Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
4.3 Europe Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
4.5 South America Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
5 North America Breast Cancer Monoclonal Antibodies Revenue by Countries
5.1 North America Breast Cancer Monoclonal Antibodies Revenue by Countries (2013-2018)
5.2 USA Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
5.3 Canada Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
5.4 Mexico Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
6 Europe Breast Cancer Monoclonal Antibodies Revenue by Countries
6.1 Europe Breast Cancer Monoclonal Antibodies Revenue by Countries (2013-2018)
6.2 Germany Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
6.3 UK Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
6.4 France Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
6.5 Russia Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
6.6 Italy Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Breast Cancer Monoclonal Antibodies Revenue by Countries
7.1 Asia-Pacific Breast Cancer Monoclonal Antibodies Revenue by Countries (2013-2018)
7.2 China Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
7.3 Japan Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
7.4 Korea Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
7.5 India Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
8 South America Breast Cancer Monoclonal Antibodies Revenue by Countries
8.1 South America Breast Cancer Monoclonal Antibodies Revenue by Countries (2013-2018)
8.2 Brazil Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
8.3 Argentina Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
8.4 Colombia Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Breast Cancer Monoclonal Antibodies by Countries
9.1 Middle East and Africa Breast Cancer Monoclonal Antibodies Revenue by Countries (2013-2018)
9.2 Saudi Arabia Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
9.3 UAE Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
9.4 Egypt Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
9.5 Nigeria Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
9.6 South Africa Breast Cancer Monoclonal Antibodies Revenue and Growth Rate (2013-2018)
10 Global Breast Cancer Monoclonal Antibodies Market Segment by Type
10.1 Global Breast Cancer Monoclonal Antibodies Revenue and Market Share by Type (2013-2018)
10.2 Global Breast Cancer Monoclonal Antibodies Market Forecast by Type (2018-2023)
10.3 Naked MAbs Revenue Growth Rate (2013-2023)
10.4 Conjugated MAbs Revenue Growth Rate (2013-2023)
11 Global Breast Cancer Monoclonal Antibodies Market Segment by Application
11.1 Global Breast Cancer Monoclonal Antibodies Revenue Market Share by Application (2013-2018)
11.2 Breast Cancer Monoclonal Antibodies Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Retail Pharmacies Revenue Growth (2013-2018)
11.5 Others Revenue Growth (2013-2018)
12 Global Breast Cancer Monoclonal Antibodies Market Size Forecast (2018-2023)
12.1 Global Breast Cancer Monoclonal Antibodies Market Size Forecast (2018-2023)
12.2 Global Breast Cancer Monoclonal Antibodies Market Forecast by Regions (2018-2023)
12.3 North America Breast Cancer Monoclonal Antibodies Revenue Market Forecast (2018-2023)
12.4 Europe Breast Cancer Monoclonal Antibodies Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Breast Cancer Monoclonal Antibodies Revenue Market Forecast (2018-2023)
12.6 South America Breast Cancer Monoclonal Antibodies Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Breast Cancer Monoclonal Antibodies Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Breast Cancer Monoclonal Antibodies Picture
Table Product Specifications of Breast Cancer Monoclonal Antibodies
Table Global Breast Cancer Monoclonal Antibodies and
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
